28035391|t|Safety and toxicology of the intravenous administration of Ang2 �€‘ siRNA plasmid chitosan magnetic nanoparticles
28035391|a|This aim of the present study was to investigate the safety and toxicology of intravenous administration of angiopoietin�€‘2 (Ang2)�€‘ small interfering (si)RNA plasmid �€‘ chitosan magnetic nanoparticles (CMNPs). Ang2 �€‘ CMNPs were constructed and subsequently administered at different doses to mice and rats via the tail vein. The acute (in mice) and chronic toxicity (in rats) were observed. The results of the acute toxicity assay revealed that the LD50 mice was >707.0 mg·kg�€‘1·d�€‘1, and the general condition of mice revealed no obvious abnormalities. With the exception of the high dose group (254.6 mg·kg�€‘1·d�€‘1), which exhibited partial lung congestion, the other groups exhibited no obvious abnormalities. Results of the chronic toxicity assay demonstrated that the non�€‘toxic dose of Ang2 �€‘ CMNPs in the rat was >35.35 mg·kg�€‘1·d�€‘1 for 14 days. The rat general condition and blood biochemistry indexes revealed no obvious abnormality. The blood routine indexes and lung/body ratio of each treatment group were higher when compared with the control group. The middle�€‘ and high�€‘dose groups exhibited chronic pulmonary congestion, whilst the low�€‘dose and control groups exhibited no abnormality. Similarly, the other organs revealed no obvious abnormality. Ang2 �€‘ CMNPs have good safety at a certain dose range and may be considered as the target drug carrier.
28035391	11	21	toxicology	T091	UMLS:C0040541
28035391	29	55	intravenous administration	T082	UMLS:C0013125
28035391	59	63	Ang2	T103	UMLS:C0540511
28035391	68	73	siRNA	T103	UMLS:C1099354
28035391	74	81	plasmid	T103	UMLS:C0032136
28035391	82	90	chitosan	T103	UMLS:C0162969
28035391	91	113	magnetic nanoparticles	T103	UMLS:C2713587
28035391	138	143	study	T062	UMLS:C2603343
28035391	178	188	toxicology	T091	UMLS:C0040541
28035391	192	218	intravenous administration	T082	UMLS:C0013125
28035391	222	238	angiopoietin�€‘2	T103	UMLS:C0540511
28035391	240	244	Ang2	T103	UMLS:C0540511
28035391	249	274	small interfering (si)RNA	T103	UMLS:C1099354
28035391	275	282	plasmid	T103	UMLS:C0032136
28035391	287	295	chitosan	T103	UMLS:C0162969
28035391	296	318	magnetic nanoparticles	T103	UMLS:C2713587
28035391	320	325	CMNPs	T103	UMLS:C2713587
28035391	328	332	Ang2	T103	UMLS:C0540511
28035391	337	342	CMNPs	T103	UMLS:C2713587
28035391	412	416	mice	T204	UMLS:C0025929
28035391	421	425	rats	T204	UMLS:C0034693
28035391	434	443	tail vein	T017	UMLS:C2985205
28035391	459	463	mice	T204	UMLS:C0025929
28035391	477	485	toxicity	T037	UMLS:C0600688
28035391	490	494	rats	T204	UMLS:C0034693
28035391	536	550	toxicity assay	T058	UMLS:C0022885
28035391	574	578	mice	T204	UMLS:C0025929
28035391	615	632	general condition	T033	UMLS:C1142435
28035391	636	640	mice	T204	UMLS:C0025929
28035391	650	674	no obvious abnormalities	T033	UMLS:C3809765
28035391	759	782	partial lung congestion	T038	UMLS:C0242073
28035391	811	835	no obvious abnormalities	T033	UMLS:C3809765
28035391	860	874	toxicity assay	T058	UMLS:C0022885
28035391	917	921	Ang2	T103	UMLS:C0540511
28035391	926	931	CMNPs	T103	UMLS:C2713587
28035391	939	942	rat	T204	UMLS:C0034693
28035391	987	990	rat	T204	UMLS:C0034693
28035391	991	1008	general condition	T033	UMLS:C1142435
28035391	1049	1071	no obvious abnormality	T033	UMLS:C3809765
28035391	1077	1098	blood routine indexes	T058	UMLS:C0022885
28035391	1103	1118	lung/body ratio	T058	UMLS:C1261161
28035391	1248	1268	pulmonary congestion	T038	UMLS:C0242073
28035391	1321	1335	no abnormality	T033	UMLS:C3809765
28035391	1358	1364	organs	T017	UMLS:C0003055
28035391	1374	1396	no obvious abnormality	T033	UMLS:C3809765
28035391	1398	1402	Ang2	T103	UMLS:C0540511
28035391	1407	1412	CMNPs	T103	UMLS:C2713587
28035391	1490	1502	drug carrier	T103	UMLS:C0013161